Novartis Thailand
Novartis Thailand is the Thai subsidiary of Novartis AG (Swiss-parent global pharmaceutical group). ~6% Thai market share by value. Therapeutic focus: oncology (Jakavi, Kisqali, Tafinlar, Mekinist, Pluvicto, radiopharmaceuticals), cardiovascular (Entresto for heart failure, Leqvio for cholesterol), ophthalmology (Lucentis, Beovu), immunology, neuroscience. Novartis has been a key biosimilar pioneer via its Sandoz division (Sandoz Thailand); 2023 Sandoz spin-off from Novartis separated the biosimilar, generics business globally.
Snapshot
Headline numbers a buyer checks first.
Thai market share
~6% by value
FY2024
Top-5 MNC pharma by value in Thailand
Parent global revenue
USD 45.7B
FY2024
Novartis AG FY2024; +11% YoY; innovative medicines only post-Sandoz spin-off
Key Thailand products
Kisqali, Entresto, Jakavi, Pluvicto, Leqvio
FY2024
Parent
Novartis AG (SIX:NOVN, NYSE:NVS)
Subsidiary since 1996
Thailand subsidiary founded
1996
Historical
Post-Sandoz positioning
Pure innovative medicines
Since Oct 2023
Sandoz listed separately as standalone generics-biosimilar company
What this subsidiary actually does
Novartis Thailand imports, markets, and distributes Novartis AG-originated pharmaceutical products. Oncology is central: Jakavi (ruxolitinib, myelofibrosis, PV), Kisqali (ribociclib, breast cancer), Tafinlar, Mekinist (melanoma combination), Pluvicto (radiopharmaceutical for prostate cancer). Cardiovascular: Entresto (heart failure, large global revenue), Leqvio (siRNA cholesterol therapy). Ophthalmology: Lucentis, Beovu (AMD, diabetic retinopathy). Channels: MoPH central procurement, hospital direct, retail pharmacy, specialty distribution.[]
Strategic position: Novartis Thailand is specialty, oncology focused; less primary-care exposed than peers. Post-2023 Sandoz separation means Novartis Thailand is pure-specialty originator. Patent-expiry trajectory, pipeline-launch timing, NLEM inclusion decisions for high-cost specialty oncology (e.g., Kisqali, Pluvicto) are the near-term variables. Entresto, Lucentis face biosimilar competition; new-oncology, radiopharmaceutical launches offset.[]
Portfolio snapshot: key Thai franchises
Novartis Thailand's product mix spans oncology, cardiovascular, and ophthalmology with global blockbusters leading.
Oncology
Kisqali, Jakavi, Pluvicto: multi-indication growth
Kisqali (ribociclib, HR+ HER2- breast cancer) is Novartis's global oncology blockbuster — global FY2024 sales USD 3.1B (+51% YoY). In Thailand, Kisqali access flows through UCS high-cost-drug programme and private hospital oncology centres. Jakavi (ruxolitinib, myelofibrosis) is a mature franchise. Pluvicto (PSMA-targeted radiopharmaceutical for prostate cancer) is the newest specialty addition — requiring radiopharmaceutical handling capability limited to a handful of Thai hospitals.[]
Cardiovascular
Entresto: largest cardiology franchise in SE Asia
Entresto (sacubitril/valsartan) for heart failure has established itself as the leading branded heart-failure therapy in Thailand's cardiologist prescribing. Global FY2024 sales USD 7.2B (+18% YoY). Thailand inclusion in National Drug List for heart failure strengthens hospital uptake. Patent expiry and biosimilar/generic entry risk is a 2026-2027 variable. Leqvio (inclisiran, siRNA cholesterol) is the next-generation cardiovascular product in Thai launch phase.[]
Ophthalmology
Lucentis, Beovu in AMD — competitive pressure from Vabysmo
Lucentis (ranibizumab) and Beovu (brolucizumab) treat age-related macular degeneration and diabetic macular oedema. Both face competition from Roche's Vabysmo (faricimab), which entered Thai ophthalmology centres from 2022-2023 with better dosing interval. Novartis ophthalmology revenue in Thailand is under pressure from the Vabysmo share shift.[]
Post-Sandoz
Pure innovative medicines — no generics, biosimilar offset
Sandoz (generics, biosimilars) was spun off from Novartis AG and listed separately in October 2023. Novartis Thailand no longer has a generics hedge. This is a strategic risk: patent cliff on Lucentis and Entresto has no internal biosimilar offset. It is also a structural strength for margin positioning — pure originator portfolio commands higher ASP in private hospital channels.[]
MNC pharma Thai market share: top originator subsidiaries
Novartis Thailand holds approximately 6% value share in a competitive MNC field.
AstraZeneca Thailand
Parent
AstraZeneca PLC
Thai market share (value)
Therapeutic focus
Oncology, respiratory, cardiovascular
Parent
Novartis AG
Thai market share (value)
~6%
Therapeutic focus
Oncology, cardiovascular, ophthalmology
Parent
Roche Holding AG
Thai market share (value)
~5%
Therapeutic focus
Oncology biologics, diagnostics
Sanofi Thailand
| MNC subsidiary | Parent | Thai market share (value) | Therapeutic focus |
|---|---|---|---|
| AstraZeneca Thailand | AstraZeneca PLC | ~10% | Oncology, respiratory, cardiovascular |
| Pfizer Thailand | Pfizer Inc. | ~8% | Oncology, vaccines, rare disease |
| Novartis Thailand | Novartis AG | ~6% | Oncology, cardiovascular, ophthalmology |
| Roche Thailand | Roche Holding AG | ~5% | Oncology biologics, diagnostics |
| Sanofi Thailand | Sanofi SA | ~4% | Rare disease, vaccines, diabetes |
Portfolio snapshot: key Thai franchises
Novartis Thailand's product mix spans oncology, cardiovascular, and ophthalmology with global blockbusters leading.
Oncology
Kisqali, Jakavi, Pluvicto: multi-indication growth
Kisqali (ribociclib, HR+ HER2- breast cancer) is Novartis's global oncology blockbuster — global FY2024 sales USD 3.1B (+51% YoY). In Thailand, Kisqali access flows through UCS high-cost-drug programme and private hospital oncology centres. Jakavi (ruxolitinib, myelofibrosis) is a mature franchise. Pluvicto (PSMA-targeted radiopharmaceutical for prostate cancer) is the newest specialty addition — requiring radiopharmaceutical handling capability limited to a handful of Thai hospitals.[]
Cardiovascular
Entresto: largest cardiology franchise in SE Asia
Entresto (sacubitril/valsartan) for heart failure has established itself as the leading branded heart-failure therapy in Thailand's cardiologist prescribing. Global FY2024 sales USD 7.2B (+18% YoY). Thailand inclusion in National Drug List for heart failure strengthens hospital uptake. Patent expiry and biosimilar/generic entry risk is a 2026-2027 variable. Leqvio (inclisiran, siRNA cholesterol) is the next-generation cardiovascular product in Thai launch phase.[]
Ophthalmology
Lucentis, Beovu in AMD — competitive pressure from Vabysmo
Lucentis (ranibizumab) and Beovu (brolucizumab) treat age-related macular degeneration and diabetic macular oedema. Both face competition from Roche's Vabysmo (faricimab), which entered Thai ophthalmology centres from 2022-2023 with better dosing interval. Novartis ophthalmology revenue in Thailand is under pressure from the Vabysmo share shift.[]
Post-Sandoz
Pure innovative medicines — no generics, biosimilar offset
Sandoz (generics, biosimilars) was spun off from Novartis AG and listed separately in October 2023. Novartis Thailand no longer has a generics hedge. This is a strategic risk: patent cliff on Lucentis and Entresto has no internal biosimilar offset. It is also a structural strength for margin positioning — pure originator portfolio commands higher ASP in private hospital channels.[]
MNC pharma Thai market share: top originator subsidiaries
Novartis Thailand holds approximately 6% value share in a competitive MNC field.
AstraZeneca Thailand
Parent
AstraZeneca PLC
Thai market share (value)
Therapeutic focus
Oncology, respiratory, cardiovascular
Parent
Novartis AG
Thai market share (value)
~6%
Therapeutic focus
Oncology, cardiovascular, ophthalmology
Parent
Roche Holding AG
Thai market share (value)
~5%
Therapeutic focus
Oncology biologics, diagnostics
Sanofi Thailand
| MNC subsidiary | Parent | Thai market share (value) | Therapeutic focus |
|---|---|---|---|
| AstraZeneca Thailand | AstraZeneca PLC | ~10% | Oncology, respiratory, cardiovascular |
| Pfizer Thailand | Pfizer Inc. | ~8% | Oncology, vaccines, rare disease |
| Novartis Thailand | Novartis AG | ~6% | Oncology, cardiovascular, ophthalmology |
| Roche Thailand | Roche Holding AG | ~5% | Oncology biologics, diagnostics |
| Sanofi Thailand | Sanofi SA | ~4% | Rare disease, vaccines, diabetes |
Watchpoints
Oncology, radiopharmaceutical pipeline
Pluvicto, pipeline expansion; NLEM inclusion for high-cost specialty.
Entresto biosimilar competition
Heart-failure therapy, patent-expiry timeline.
Ophthalmology Lucentis, Beovu
AMD, diabetic-retinopathy market share vs Roche Vabysmo, generics.
Post-Sandoz specialty focus
Pure-specialty positioning without generics, biosimilar hedge.
Related Market profiles
Peers, parents, partners, agencies, and other Pharmaceuticals actors.
Competitor
Pfizer Thailand
Oncology, specialty peer.
Open Market profile →
Competitor
Roche Thailand
Oncology, ophthalmology direct competitor.
Open Market profile →
Competitor
GSK Thailand
MNC originator peer; different therapeutic-area emphasis.
Open Market profile →
Sector peer
Government Pharmaceutical Organisation (GPO)
Thai state pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~ $463.8M.
Open Market profile →
Sources + data provenance
Every filing, filing-adjacent register, or trusted industry source cited in this profile.
Novartis Thailand — Subsidiary Disclosures
| Source | Publisher | Grade | As of |
|---|---|---|---|
| Novartis Thailand — Subsidiary Disclosures | Novartis Thailand (MNC subsidiary) | Supporting | 2025-12-31 |
Reports featuring this profile
Thailand Precision Medicine & Genomics 2027 Market Intelligence
Pharma-paired CDx and patient access for Lynparza BRCA, Tagrisso EGFR, Keytruda PD-L1; co-pay and bundle pilot programmes.
Open report →
Sits alongside 4 other Atlas profilesThailand Pharmaceuticals Market Intelligence
Swiss-parent MNC specialty subsidiary; oncology, cardiovascular, ophthalmology; ~6% Thai market share.
Open report →
Sits alongside 7 other Atlas profilesThailand Pharma Generic vs Branded Deep Dive
Novartis Thailand branded innovator MNC.
Open report →
Sits alongside 7 other Atlas profilesRelated Market profiles
competitor
Pfizer Thailand
US-parent MNC originator Thai subsidiary; oncology, primary care, vaccines; ~7% Thai market value share.
competitor
Roche Thailand
Swiss-parent MNC specialty Thai subsidiary; oncology, biologics, diagnostics; ~5% Thai market value share.
competitor
GSK Thailand
UK-parent MNC originator Thai subsidiary; respiratory, vaccines, HIV, oncology; ~8% Thai market value share.